We are an affiliate: if you order from Growth Guys using this code we earn a commission, at no extra cost to you. We are not Growth Guys and have no ownership of or role in the company.
KPV is a three-residue fragment of a naturally occurring hormone, studied for anti-inflammatory signalling.
KPV is a three-residue fragment of a naturally occurring hormone, studied for anti-inflammatory signalling. The parent molecule has a substantial literature; the fragment has a small one, and findings about the parent are not automatically findings about the fragment.
What exists is largely cell and animal work from a modest number of groups. There is no body of human trial evidence, and the volume of discussion online considerably exceeds the volume of research.
A three-residue sequence is straightforward to synthesise, which lowers the barrier to supply and means more of the market is plausible-looking material from unverified sources. That makes identity confirmation more valuable here than for a compound only a few facilities can make.
A small number of assays relative to other items here. We publish the count rather than implying a depth we do not have — a thin record stated plainly is more useful than a thin record described as 'tested'.
An interesting fragment with a real but small preclinical literature and no human trial evidence. Anything stronger than that is an extrapolation from the parent molecule.
The published set we counted contains 4 report(s) naming KPV, averaging 99.63% purity. Each resolves on the testing laboratory's own portal rather than as a file hosted by the seller.
A compound studied many times in cells and animals can still have no human evidence at all. Counting papers measures attention, and the question that matters is how far up the evidence hierarchy any of them reach.
Moving from preclinical work to human trials requires funding and a commercial case. Absence of trials frequently reflects that economics rather than a scientific verdict, which is worth separating when reading a thin human literature.
Preclinical work often uses a route no person would use, and results from it do not carry across. Checking how a substance was administered in the cited studies frequently explains why a promising finding has not produced a human trial.
The claims on this page about a three-amino-acid fragment with a small literature, where the honest answer is that there is not much to report can be checked against sources outside this site: